{"id":"W2343845543","doi":"10.1007/s10549-016-3812-1","title":"Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer","year":2016,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"ca_institutions":"Queen's University; Hôpital Charles-Le Moyne; Juravinski Cancer Centre; University Health Network; Hamilton Health Sciences; Princess Margaret Cancer Centre; Kingston General Hospital; Interior Health; Ottawa Hospital; BC Cancer Agency; Queen Elizabeth II Health Sciences Centre","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Ipsen; AstraZeneca; Celgene; Genomic Health; Cancer Care Ontario; Pfizer; Cancer Research Institute","keywords":"Medicine; Internal medicine; PTEN; Cancer; Breast cancer; Oncology; Response Evaluation Criteria in Solid Tumors; Progressive disease; Metastatic breast cancer; Triple-negative breast cancer; Estrogen receptor; Clinical endpoint; Adverse effect; Clinical trial; Disease; Biology; PI3K/AKT/mTOR pathway","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001381622,0.000674206,0.0016748,0.0009543069,0.0004669993,0.0000819823,0.0002619687,0.0001548958,0.003984525],"category_scores_gemma":[0.000207239,0.0003729746,0.00009991584,0.001014494,0.0006756654,0.0003341337,0.0001884327,0.0004918258,0.000007406356],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005713955,"about_ca_system_score_gemma":0.003653938,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.4795882,"about_ca_topic_score_gemma":0.4854969,"domain_scores_codex":[0.9929707,0.001343349,0.001095467,0.001303959,0.001655002,0.001631541],"domain_scores_gemma":[0.9956778,0.0005572193,0.0003778956,0.0005508632,0.001193279,0.001642985],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02663769,0.006821732,0.5959875,0.0002630951,0.001418397,0.00004651924,0.002815307,2.170382e-7,0.0007413381,0.00002745867,0.0007006662,0.3645401],"study_design_scores_gemma":[0.1231086,0.07292167,0.7889726,0.005066504,0.0004926612,0.00004534132,0.002248759,0.000004951173,0.004357934,0.00005217868,0.001802541,0.0009263007],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9699857,0.001224556,9.642941e-7,0.004991568,0.0001315245,0.008871657,0.01474207,0.00002829717,0.00002362292],"genre_scores_gemma":[0.987022,0.003249029,0.0001366126,0.00003342523,0.0002385433,0.00857873,0.0001310625,0.0001159756,0.0004945531],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3636138,"threshold_uncertainty_score":0.9998722,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1276228540309587,"score_gpt":0.4400756633405633,"score_spread":0.3124528093096046,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}